Paola Guglielmelli

95PUBLICATIONS
193CO-AUTHORS
Molecular targetsHaematological tumoursAutoimmunityImmunogenetics (incl. genetic immunology)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (95)

|Oct 08, 2026
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.

|Jul 11, 2026
Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.

|Apr 20, 2026
APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications.

|Mar 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Paola Guglielmelli, Massimo Breccia, Francesco Mendicino

|Mar 06, 2026
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.

Niccolò Bartalucci, Francesco Mannelli, Danilo Tarantino

|Mar 05, 2026
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Barbara Mora, Francesca Palandri, Paola Guglielmelli

Pageof 16

Frequent Collaborators

50 joint publications

Alessandro Maria Vannucchi

23 joint publications

Giuseppe Gaetano Loscocco

21 joint publications

Tiziano Barbui

20 joint publications

Valerio De Stefano